TH

Across TCGA pan-cancer cohorts, TH Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TH data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TH expression acts as an unfavorable survival marker.

LIHC, SKCM, and BLCA are the cancer types where TH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.238	0.690	.012	12	view →
SKCM	DFS	Median	All	0.209	0.763	<.001	12	view →
BLCA	DFS	Median	All	0.163	0.625	.018	9	view →
SCLC	DFS	Median	All	0.256	0.577	.036	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	OS	Median	All	0.182	0.514	.023	4	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TH–LIHC (OS)

Open the LIHC breakdown →